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http://dxObjectives: Anatomic resection is currently the standard of care for clinical stage I lung cancer, yet clinicians
increasingly pursue nonsurgical, ablative therapies to avoid the morbidity of thoracotomy. The video-assisted
thoracic surgery (VATS) approach is a minimally invasive alternative to thoracotomy yet the effect of VATS
on the morbidity of patients undergoing lung cancer resection is not fully characterized. We evaluated compli-
cations following anatomic resection of clinical stage I lung cancer by VATS and thoracotomy to clarify the
effect of the minimally invasive approach.
Methods: The Society of Thoracic Surgeons database was queried for lobectomies and segmentectomies
performed between 2001 and 2010 for clinical stage I primary cancer.
Results: A total of 11,531 (7137 open and 4394 VATS) patients with clinical stage I primary lung cancers
underwent resection. Propensity scoring was used to match cases into 2745 well-balanced pairs. Overall com-
plications were significantly more likely in the thoracotomy group (36%) than in the VATS cohort (30%;
P< .001). Patients undergoing thoracotomy experienced significantly more pulmonary complications (21%
vs 18%), atrial arrhythmias (13% vs 10%), and were more likely to undergo transfusion (6% vs 4%). Operative
mortality was similar (thoracotomy 1.8%, VATS 1.3%; P ¼ .13).
Conclusions:Anatomic resection of early stage lung cancer is performed with a low mortality rate, according to
data from the Society of Thoracic Surgeons database. Perioperative complications are significantly less likely to
occur when patients with stage I lung cancers undergo resection using the VATS approach. Further study is war-
ranted to determine long-term effects of these differences in perioperative outcomes. (J Thorac Cardiovasc Surg
2014;148:637-43)G
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Stage I lung tumors are likely to become most common
presentation of primary lung cancer as a result of progres-
sive adoption of screening with computed tomography
scanning. Results from the landmark National Lung
Screening trial suggest the prevalence of stage I non-small
cell lung cancer (NSCLC) at presentation will increase
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The Journal of Thoracic and CaTherefore a comprehensive understanding of treatment-
associated morbidity in early stage lung cancer is critical.
Anatomic pulmonary resection is currently the standard
of care for the treatment of clinical stage I lung cancer,2
yet concerns over the morbidity associated with a traditional
thoracotomy have motivated patients and clinicians to
pursue less-invasive strategies for lung cancer management.
Video-assisted thoracic surgery (VATS) is a minimally inva-
sive alternative to thoracotomy for anatomic lung cancer
resection that is associatedwith less discomfort, shorter hos-
pitalization, and a faster recovery.3,4 However, the effect of
surgical approach on complication rates in clinical stage I
cancer has been incompletely addressed. Therefore, we
examined complication rates following anatomic resection
in patients with clinical stage I NSCLC via VATS and
thoracotomy by Board-certified thoracic surgeons to
determine the result of approach on operative morbidity.
METHODS
TheSociety ofThoracicSurgeonsGeneralThoracicDatabase (STS-GTD)
was queried for surgically managed primary lung cancer. Eligible patients
included those undergoing anatomic pulmonary resections for treatment
na€ıve, clinical stage T1 N0 M0 and T2 N0 M0 primary lung cancer in the
STS-GTD between 2001 and 2010. During 2009, the stage classification sys-
temwasmodified from the sixth edition of the American Joint Committee on
Cancer staging manual (56% of our study population), to the seventh edition
(44%). Of the 24,626 primary lung cancer patients in the STS-GTD, 18,928rdiovascular Surgery c Volume 148, Number 2 637
Abbreviations and Acronyms
NSCLC ¼ non-small cell lung cancer
STS-GTD ¼ Society of Thoracic Surgeons General
Thoracic Database
VATS ¼ video-assisted thoracic surgery
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S(77%) contained sufficiently complete clinical staging information to be
considered. This figure improved over the course of the study, with 93% of
cases containing complete clinical staging information in 2009 and 2010.
We excluded patients with missing data for the pathologic N variable, or
who were pathologically staged to be N3 (8 patients). The study population
contained insufficient numbers of minimally invasive pneumonectomies
(VATS ¼ 17 patients), bilobectomies (VATS ¼ 70), and sleeve lobectomies
(VATS¼ 10) for meaningful comparison and were therefore excluded from
both cohorts. The current version of the database does not distinguish
VATS segmentectomies from VATS lobectomies and therefore lobectomies
and segmentectomies were analyzed as a combined group for both
thoracotomy and VATS cohorts for the entire study period. The rates of
segmentectomy in the previous version of the database that did distinguish
VATS lobectomy from segmentectomy (STS-GTD2.07) were similar (thora-
cotomy 6.5% and VATS 8%). Between 2001 and 2010, a total of 11,531
lobectomies or segmentectomies (7137 via thoracotomy and 4394 VATS)
for clinical stage I primary lung cancer were recorded in the STS-GTD.
The STS-GTD is a voluntary database, but participants are bound by
contract to submit complete unselected cases and are provided with yearly
reports concerning missing or outlier data. The STS-GTD has been
subjected to external audit annually, beginning in 2010. Approximately
5% of the data were audited and the overall accuracy was 93%.
Conversions
There is not a field in the STS-GTD to indicate a conversion from VATS
to thoracotomy. However in version 2.07 of the STS-GTD data form an
approach field exists that allows abstractors to select>1 approach. Cases
of lobectomy or segmentectomy coded with both thoracoscopy and thora-
cotomy as the surgical approach were considered combined procedures
(potentially representing conversions). Version 2.081 allowed primary
procedures as well as secondary procedures to be captured. Primary
procedures coded as lobectomy or segmentectomy by thoracotomy, with
a secondary VATS procedure on the same day were considered to have
had a combined approach (potentially representing a conversion).
Statistics
The Duke Clinical Research Institute supervised all statistical analysis.
Comparisons of patient characteristics between groups were made using
the 2-sample nonparametric Wilcoxon test for continuous variables and
the c2 test for categorical variables. Multivariable analysis utilized logistic
regression. P values were not adjusted for multiplicity.
Annual study case volume of lobectomy or segmentectomy for clinical
stage I primary lung cancer (N ¼ 11,531) was estimated for each of the
providers. Surgeons were identified by their national provider identifier
number (years 2009-2010) or surgeon name, national provider identifier
when available, and participant number. Out of 11,531 study cases, surgeon
information was missing for 350 operations (3%). Yearly study case
volume of lobectomy or segmentectomy for clinical stage I primary lung
cancer was averaged during the surgeon’s activity period (or if the activity
period was shorter than 6 months, estimated over the interval between case
submission and data harvest date for the year in question, with 2months as a
minimum activity period). For incorporation into a multivariable analysis,
the surgeons were divided into quartiles with the following annual volume
distributions: 0.7 and<10, 10 and<17, 17 and<27, and 27 and
70.2.638 The Journal of Thoracic and Cardiovascular SurgA multivariable analysis was performed using patients with complete
information (n ¼ 8310) for 23 variables (use of mediastinal staging proce-
dure, clinical T stage, age, gender, race, body mass index, predicted forced
expiratory volume in 1 second, predicted diffusing capacity of carbonmon-
oxide, year of surgery, clinical status at time of surgery, general thoracic
reoperation, prior thoracic surgery, laterality, American Society of Anes-
thesiologists risk class, smoking status, Zubrod score, weight loss in 3
months before admission, hypertension, use of steroids, congestive heart
failure, coronary artery disease, peripheral vascular disease, and renal
insufficiency). A full list of data fields in the STS-GTD can be found at
http://www.sts.org/quality-research-patient-safety/national-database/data
base-managers/general-thoracic-surgery-databa-1.
In an attempt to eliminate potentially confounding differences in the
patient populations within the 2 cohorts, a propensity-matched analysis was
performed as described in our previous publication using this dataset.5 A
patient’s propensity for having undergone a VATS procedure was
determined by a logistic regressionmodel using 23 preoperative patient char-
acteristics as independentvariables (seeabovemultivariabledescription).The
estimated probability of havingundergone aVATSprocedurewas determined
as apropensity score andused tomatchpairsof patients undergoingVATSand
thoracotomy using a Greedy 5 to 1 digit algorithm,6 similar to the propensity
strategy used in previous report from the STS-GTD.3 The majority of pairs
had differences in propensity score<0.0001 and matched pairs were not
formed if propensity score difference exceeded 0.1. The missing data for
complications averaged 0.7% for the variables. There was no difference in
the frequency of missing data for the complications by approach in the
open and VATS cohorts, with the exception of discharge with chest tube, in
which the data was missing in 1.1% of open and .5% of VATS patients
(P<.001). The database analysis interprets a failure to indicate the presence
of a complication as the absence of that particular complication.
RESULTS
Patients
The patient and tumor attributes of the thoracotomy and
VATS groups are listed in Table 1. Several important
differences were identified, including a greater frequency of
T1 tumors in theVATScohort (76%vs65%;P<.001) andbet-
ter pulmonary function in VATS cohort (ie, predicted forced
expiratory volume in 1 second of 83% vs 78%; P< .001).
The VATS procedures were performed by surgeons that aver-
agedmore lobectomies for clinical stage I primary lung cancer
each year (median, 20.4 vs 15.7 procedures per year;P<.001).
Multivariable Analysis of Complication Risk
Overall, 34% of patients experienced at least 1 complica-
tion. Patients undergoing thoracotomy were more likely to
experience a complication (36.4%) than the VATS patients
(28.9%) (P<.001). A multivariable analysis was performed
to identify risk factors for the development of complications,
and variables associatedwith a significant effect on complica-
tion risk are shown in Table 2. The VATS approach was asso-
ciated with a lower risk of complications than thoracotomy
(odds ratio, 0.775; 95% confidence interval, 0.702-0.856;
P<.001). Increasing annual surgeon volume of lobectomy
and segmentectomy for clinical stage I primary lung cancer
was associated with a reduction in complication risk, with
surgeons performing>27 per year having significantly fewer
complications than surgeons performing<10 per year (odds
ratio, 0.783; 95% confidence interval, 0.686-0.894;P<.001).ery c August 2014
TABLE 1. Patient, tumor, and procedure characteristics
Thoracotomy
(n ¼ 7137)
Video-assisted
thoracic
surgery
(n ¼ 4394) P value
Clinical stage (%) <.001
T1 64.6 76.1
T2 35.4 23.9
Extent of resection (n [%])
Lobectomy 6667 (93.4) 1948 (92)*
Segmentectomy 470 (6.6) 170 (8)*
Estimated yearly surgeon
volume* (median
[interquartile range])
16.2 (9.1-27.2) 19.8 (12.3-28.9) <.001
Age at time of surgery (y) .032
Mean  standard
deviation
67.3  10.3 67.9  10.2
Range 18-96 21-95
Gender (%)
Female 50.6 56.8 <.001
Race (%) <.001
White 88.4 87.7
Black 8.4 7.6
Hispanic 1.6 2.0
Asian 1.6 2.7
Body mass index (%)
>35 10.3 8.3 <.001
FEV1 (% predicted)
Mean  standard
deviation
78.5  22 83  22.8 <.001
DLCO (% predicted)
Mean  standard
deviation
72.3  22.7 75.2  22.6 <.001
Year of surgery (%) <.001
2001-2004 12.6 3.1
2005 9.1 3.5
2006 11.2 8.1
2007 12.2 13.7
2008 15.7 19.8
2009 26.9 34.1
2010 12.3 17.7
Clinical status (%) <.001
Elective 95.3 98.2
Urgent 3.5 .7
Emergent 1.2 1.1
General thoracic
reoperation (%)
<.001
Yes 4.5 2.7
Laterality of procedure (%) .004
Right 57.4 60.2
American Society of
Anesthesiologists
risk class (%)
<.001
I-II 18.4 24.2
III 69.6 70.2
IV-IV 12 5.6
(Continued)
TABLE 1. Continued
Thoracotomy
(n ¼ 7137)
Video-assisted
thoracic
surgery
(n ¼ 4394) P value
Cigarette smoker (%) .047
Ever 85.1 83.7
Med staging procedure (%)y <.001
Day of surgery or 45 d 69.4 80.3
FEV1, Forced expiratory volume in 1 second; DLCO, carbon monoxide diffusing ca-
pacity. *Estimated surgeon volume was calculated by dividing the number of study
cases (the 11,531 lobectomies and segmentectomies) performed by the surgeon
over the time frame in which the surgeon submitted cases. yMed staging procedure
includes mediastinoscopy, anterior mediastinoscopy, mediastinal lymph node biopsy,
extended cervical mediastinoscopy, mediastinal lymph node dissection, mediastinal
lymph node sampling, thoracoscopy diagnostic mediastinal space with biopsy, endo-
bronchial ultrasound, and thoracic lymphadenectomy.
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To account for potentially confounding differences in the
approach-stratified cohorts, a propensity analysis with
matching was performed resulting in 2745 well-balanced
matched pairs. Table 3 demonstrates that the VATS and tho-
racotomy cohorts were extremely well matched, with the
exception of surgeon volume, which was not included in
the propensity score.
The length of stay was shorter in the VATS cohort
(mean, 5.6  8.4 days for VATS vs 7.1  7.0 days for
thoracotomy; P< .001). Complication rates were higher
in the thoracotomy cohort (36% vs 30%; P < .001)
(Table 4). Operative mortality was not significantly
different in the 2 groups (1.8 vs 1.3%; P ¼ .13).
Pulmonary complications were higher in the thoracotomy
cohort (eg, pneumonia: 4.6% in the thoracotomy group
and 3.4% in the VATS group), as were cardiovascular
complications (eg, atrial fibrillation: 12.7% in thoraco-
tomy patients and 9.7% in VATS patients) and the need
for blood transfusion (6.2% in the thoracotomy group vs
4.0% in the VATS group).
Infectious complications were similar between the 2
cohorts (thoracotomy 3.6% vs VATS 3.0%; P ¼ .17).
Prolonged air leak was not different between the 2 groups
(10.9% vs 10.7%) but discharge home with a chest
tube was higher in the VATS cohort (8.4% VATS vs
5.9% thoracotomy; P<.001).
Readmissions were examined as a postoperative event.
However readmissions within 30 days of surgery were not
captured by the STS-GTD before 2009. Among
propensity-matched cases, readmissions within 30 days of
surgery were similar between the thoracotomy (81 out of
1386) and VATS (94 out of 1418) approaches (5.5% and
6.2%, respectively; P ¼ .42). Because roughly half of the
propensity-matched cases lacked this outcome variable
(before 2009), we also examined readmissions in the un-
matched groups. Among patients undergoing resection inrdiovascular Surgery c Volume 148, Number 2 639
TABLE 2. Multivariable analysis (n ¼ 8310) of risk to develop any
postoperative complication
Characteristic
Odds
ratio
95%
Confidence
interval P value
Approach (VATS vs open) 0.763 0.691-0.842 <.001
Average annual surgeon volume
0.7 and<10* 1.00 <.001
10 and<17 0.967 0.848-1.104
17 and<27 0.837 0.7270-0.964
27 and 70.2 0.783 0.686-0.894
Age at time of surgery 1.030 1.025-1.035 <.001
Race
White* 1.00 .002
Black 0.718 0.599-0.860
Hispanic 0.768 0.519-1.37
Asian 0.923 0.640-1.332
FEV1 (% predicted) 0.991 0.989-0.994 <.001
Thoracic reoperation (yes vs no) 1.656 1.317-2.081 <.001
American Society of Anesthesiologists
risk class
I-II* 1.00 <.001
III 1.319 1.155-1.507
IV-V 1.641 1.363-1.976
Cigarette smoking (ever vs never) 1.392 1.200-1.615 <.001
Zubrod score
0 – normal activity* 1.000
1 – symptoms by fully ambulatory 1.064 0.964-1.173 .001
2 – symptoms, in bed<50% of time 1.516 1.225-1.877
3 – symptoms, in bed>50% but
<100%
1.525 0.977-2.382
Steroids (yes vs no) 1.489 1.182-1.877 .001
Peripheral vascular disease (yes vs no) 1.215 1.056-1.399 .007
Renal insufficiency (yes vs no) 1.636 1.264-2.118 <.001
VATS, Video-assisted thoracic surgery; FEV1, forced expiratory volume in 1 second.
*The risk of complications among subsequent subsets were compared with complica-
tions in the first subset.
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tween the thoracotomy (167 out of 2607) andVATS (149 out
of 2156) cohorts (6.4% and 6.9%, respectively; P ¼ .52).
Evaluation of Conversion Effect
It is possible that particularly complex VATS cases or
those with intraoperative complications were converted to
thoracotomy, thereby biasing outcome results against thora-
cotomy procedures. The STS-GTD does not contain a field
to represent conversion per se; however, in both versions of
the database there were indicators to determine if VATS and
open procedures were performed on the same day (see the
Methods section). A total of 1292 patients were coded as
having a VATS approach procedure in addition to thoracot-
omy for lobectomy or segmentectomy (representing 18.1%
of the thoracotomy cohort).
The more recent version of the database form (version
2.081) differentiates the secondary VATS procedures,
which included most commonly diagnostic thoracoscopy640 The Journal of Thoracic and Cardiovascular Surgof lungs and pleura (57%), therapeutic wedge resection
(22%), and thoracoscopy of mediastinal space (2%).
The use of both VATS and thoracotomy was not associ-
ated with a higher complication rate compared with thora-
cotomy alone (38.5% vs 35.9%; P ¼ .071). However, the
VATS cohort remained less likely to experience a complica-
tion, even when the combined approach cases (potentially
containing converted cases) were excluded from the thora-
cotomy cohort (28.9% vs 35.9%; P<.001).
DISCUSSION
Overall, postoperative complications were reported in
34% of patients after lobectomy or segmentectomy for clin-
ical stage I lung cancer in the STS-GTD. The database re-
flects the experience of Board-certified thoracic surgeons
and the complication rates compare favorably to databases
with more heterogeneous surgical representation. For
example the Health Care Utilization Project reported a
complication rate for lobectomy of 43%, whereas the Sur-
veillance, Epidemiology, and End Results Medicare data-
base reported a complication rate of 56% (Table 5).
Similarly the operative mortality for early stage lung cancer
in the STS-GTD (1.4%) appears considerably lower than
databases containing surgeons with more diverse back-
grounds (the Health Care Utilization Project 3.2% and Sur-
veillance, Epidemiology, and End Results 3.6%).7,8
The VATS approach to anatomic lung cancer resection was
associated with significantly fewer complications than thora-
cotomy in STS-GTD, a finding that echoes reports from the
National SurgicalQuality ImprovementProgram,9 theHealth-
care Utilization Project,10 as well as earlier studies from the
STS-GTD3,11 (Table 5). Our study represents the largest study
to date to evaluate treatment-associated morbidity in surgi-
cally managed, clinical stage I primary lung cancer.
The comprehensive classification of complications by the
STS-GTD database has allowed the VATS effect on surgical
morbidity to be more fully characterized. A reduction in pul-
monary complications in theVATScohort is perhaps themost
intuitive, because of the reduction in chest wall and lung
manipulation and postoperative pain. The finding that air
leak prevalence was similar between VATS and thoracotomy
cohorts (or perhaps even worse, because more VATS patients
were discharged with a chest tube potentially representing an
air leak) is a bit surprising. The proponents of VATS typically
advocate a fissureless technique (thereby avoiding instru-
mentation of the fissure, a maneuver suspected of generating
air leaks).12 Possible explanations could be variable adher-
ence to fissureless principles by VATS surgeons adopting
the technique, or alternatively the use of the fissureless tech-
nique by surgeons performing lung cancer resections via tho-
racotomy. Finally, this could reflect a difference in surgeon
comfort with patients being discharged with chest tubes.
Our study identified a significantly lower incidence of
postoperative atrial fibrillation (25% fewer cases) whenery c August 2014
TABLE 3. Patient, tumor, and procedure characteristics in
propensity-matched cohorts
Thoracotomy
(n ¼ 2745)
Video-assisted
thoracic
surgery
(n ¼ 2745)
P
value
Clinical stage (%) .67
T1 74.0 73.4
T2 26.0 26.6
Age at time of surgery (y) .94
Mean  standard deviation 68.1  9.9 68.2  10
Estimated yearly surgeon
volume* (median
[interquartile range])
15.7 (9-26.6) 20.4 (12.5-29.2) <.001
Gender (%) .98
Female 54.2 54.2
Race (%) .90
White 88.9 89.3
Black 7.5 7.5
Hispanic 1.6 1.5
Asian 2.0 1.7
Body mass index (%) .85
35 90.3 90.4
>35 9.7 9.6
FEV1 (% predicted) .73
Mean  standard deviation 81.3  21.4 80.7  22.3
DLCO (% predicted) .63
Mean  standard deviation 73.5  22.4 74.0  22.3
Year of surgery (%) .97
2001-2004 2.7 2.4
2005 3.8 3.4
2006 7.9 8.1
2007 11.8 12.1
2008 16.7 16.4
2009 38.4 38.2
2010 18.7 19.4
Clinical status (%) .74
Elective 98.1 97.9
Urgent 0.7 0.8
Emergent 1.2 1.3
General thoracic
reoperation (%)
.27
Yes 3.8 3.2
Prior thoracic surgery (%) .71
Yes 12.3 12.0
Laterality of procedure (%) .76
Right 58.6 59.0
American Society of
Anesthesiologists risk
class (%)
.98
I-II 18.7 18.8
III 74.3 74.1
IV-IV 7.0 7.1
Cigarette smoker (%) .49
Never 14.4 13.7
Ever 85.6 86.3
(Continued)
TABLE 3. Continued
Thoracotomy
(n ¼ 2745)
Video-assisted
thoracic
surgery
(n ¼ 2745)
P
value
Zubrod score .45
0 46.9 47.2
1 48.2 47.8
2 3.9 4.3
3 .8 .7
4 .1 0
Weight loss 3 mo before
admission (kg)
.90
Mean  standard deviation 0.6  3.0 0.7  3.6
Hypertension (% yes) 66.3 66 .80
Steroid use (% yes) 3.7 3.6 .83
Congestive heart failure
(% yes)
3.5 2.9 .25
Coronary artery disease
(% yes)
22.7 22.7 .97
Peripheral vascular disease
(% yes)
10.7 11.1 .63
Renal insufficiency (% yes) 2.9 2.5 .35
FEV1, Forced expiratory volume in 1 second; DLCO, carbon monoxide diffusing
capacity. *Estimated surgeon volume was calculated by dividing the number of study
cases (11,531 lobectomies and segmentectomies) performed by the surgeon over the
time frame in which the surgeon submitted cases.
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previous STS database study, but is contrary to other large
institutional series.13 The implications of this reduction in
atrial fibrillation are considerable, because the effect of
perioperative atrial fibrillation on a patient’s quality of life
and overall health care expenditures is significant and ex-
tends beyond hospitalization.14
Readmissions in our study were similar to rates recently
reported for lung cancer surgery.15 It is unclear why the re-
admissions did not differ by approach, but likely reflects a
lack of difference in the types of complications that lead
to readmission.
We explored the possibility that the lower complication
rates in the VATS cohort were secondary to greater surgical
experience among the surgeons performingVATSprocedures.
We did in fact find that the VATS procedures were done by
surgeons with a greater annual volume (median, 20.4 cases
per year for VATS vs 15.7 cases for thoracotomy). However,
a multivariable analysis demonstrated that the effect of
approach (VATS having fewer complications) remained sig-
nificant when adjusting for differences in volume. Therefore,
the thoracotomy approach appears to be an independent risk
factor for complications in patientswith clinical stage I cancer.
It was not possible to determine which patients were
converted from VATS to thoracotomy, which has the po-
tential to bias against the outcomes of the thoracotomy
group. Although it is encouraging that complication ratesrdiovascular Surgery c Volume 148, Number 2 641
TABLE 4. Complications by surgical approach in propensity-matched
cases
Thoracotomy
(n ¼ 2745)
Video-assisted
thoracic
surgery
(n ¼ 2745)
P
value
Operative times (min) <.001
Median (interquartile
range)
145 (109-196) 173 (128-220)
Length of stay (median d) 5 4 <.001
Interquartile range (4-8) (3-6)
Length of stay>14 d* (%) 7.4 4.3 <.001
Operative mortality (hospital
or 30-d) (%)
1.8 1.3 .12
Readmission within 30 d of
surgery (%)y
5.5 6.2 .42
Any complication (%) 36.2 29.9 <.001
Any pulmonary
complication (%)
20.8 18.3 .017
Air leak>5 d postoperation 10.9 10.7 .90
Patient discharged with
chest tube
5.9 8.4 <.001
Atelectasis requiring
bronchoscopy
4.1 2.7 .005
Pneumonia 4.6 3.4 .033
Adult respiratory distress 1.1 0.5 .006
Bronchopleural fistula 0.3 0.3 1
Pulmonary embolus 0.4 0.3 .51
Initial vent support>48 h 0.8 0.4 .076
Reintubation 4.3 2.8 .003
Tracheostomy 1.2 1 .51
Any cardiovascular
complication (%)
15 11.3 <.001
Atrial arrhythmia requiring
treatment
12.7 9.7 <.001
Ventricular arrhythmia
requiring treatment
0.9 0.5 .057
Myocardial infarction 0.3 .2 .44
Deep vein thrombosis
requiring treatment
0.5 0.4 .84
Any hematology
complication (%)
8.6 5.4 <.001
Bleeding requiring
reoperation
1.1 1.3 .46
Blood transfusion
intraoperatively
2.8 1.1 <.001
Blood transfusion
postoperatively
6.2 4 <.001
Any infectious
complication (%)
3.6 3 .17
Urinary tract infection 2.1 2 .70
Empyema requiring
treatment
0.6 0.3 .041
Wound infection 0.4 0.4 .83
Sepsis 0.9 0.4 .013
Any neurologic
complication (%)
3.7 2.3 .003
(Continued)
TABLE 4. Continued
Thoracotomy
(n ¼ 2745)
Video-assisted
thoracic
surgery
(n ¼ 2745)
P
value
New central neurologic event 0.7 0.4 .19
Recurrent laryngeal nerve
paresis
0.3 0.1 .058
Delirium 2 1.3 .045
New renal failure or creatinine
23 preoperative (%)
2 1.1 .006
*>14 days was defined as prolonged length of stay by previous Society of Thoracic
Surgeons analysis.16 yOnly patients undergoing surgery during 2009 or later are
included in this analysis because the variable was not captured in the Society of
Thoracic Surgeons-General Thoracic Database before 2009.
General Thoracic Surgery Boffa et al
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of cases with multiple approaches listed, without a specific
conversion data field it is not possible to distinguish con-
versions from true diagnostic procedures before a planned
thoracotomy.Limitations
The principle limitations include a potential for selection
bias for cases submitted to the database, because participa-
tion is voluntary. In addition, it is possible that patients un-
dergoing VATS were healthier in ways not captured by the
database. The database cannot distinguish conversions from
VATS to thoracotomy; therefore, these particularly chal-
lenging cases would be coded in the thoracotomy group.
The differences in atrial fibrillation prevalence and other
complications may reflect other aspects of perioperative
management unrelated to surgical approach (such as use
of perioperative beta blockers or improved pulmonary
toilet). We attempted to exclude surgeon volume as a
confounder of the approach effects. The effect of approach
on complications remained independent of volume effects
in multivariable analysis. However, we only considered vol-
ume within the case series (11,531 clinical stage I lobec-
tomies and segmentectomies), and therefore we may have
underestimated the surgical experience of surgeons who
perform significant numbers of resections for more
advanced primary lung cancer (clinical stage II or III) or
benign disease. We also did not separate surgeon case vol-
ume into VATS from thoracotomy annual experience,
recognizing the possibility that the importance of
approach-specific experience may be missed.CONCLUSIONS
Postoperative complications are less common following
anatomic resection of clinical stage I lung cancer performed
by Board-certified thoracic surgeons using the VATS
approach instead of thoracotomy. This should be taken
into consideration when counseling patients for surgery.ery c August 2014
TABLE 5. Comparison of complications by approach for lobectomy or segmentectomy for lung cancer in the literature
Database Total complications Thoracotomy
Video-assisted
thoracic surgery
P
value*
Healthcare Utilization Project-National Inpatient Sample10 2657/6292 (42.2) 2074/4769 (43.5) 583/1523 (38.3) <.001
American College of Surgeons National Surgical Quality Improvement Program9 496/2353 (21.1)y 412/1737 (23.7)y 84/616 (13.6)y <.001
Surveillance, Epidemiology, and End Results8 2329/4171 (55.8) NA NA NA
Society of Thoracic Surgeons previous report – all stagesz,3 780/2562 (30.4) 444/1281 (34.7) 336/1281 (26.2) <.001
Society of Thoracic Surgeons current report – clinical stage Iz 1816/5490 (33.1) 994/2745 (36.2) 822/2745 (29.9) <.001
Data are presented as n (%). NA, Not available. *Between thoracotomy and video-assisted thoracic surgery. yAtrial fibrillation not included. zPropensity-matched cohorts.
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